Abstracts tagged "scleroderma and treatment options"

Abstract Number: 2671 • 2017 ACR/ARHP Annual Meeting
Bosentan in Scleroderma Renal Crisis: A National Open Label Prospective Study
Alice Bérezné^1,2, Hendy ABDOUL³, Alexandre Karras⁴, Isabelle Marie⁵, Antoine Huart⁶, Maxence Ficheux⁷, Viviane Queyrel⁸, Bernard Imbert⁹, Xavier Puéchal¹, Arnaud Hot¹⁰, Boris Bienvenu¹¹, Elisabeth Diot¹², Bruno Moulin¹³, Thomas Quémeneur¹⁴, Jean-Emmanuel Kahn¹⁵, Luc Mouthon¹ and Loïc Guillevin for the French Vasculitis Study Group¹, ¹Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ²Centre de Compétence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Centre de Compétence Eosinophiles CEREO, Hôpital Annecy Genevois, Anency, France, ³Centre d'investigation Clinique Paris Descartes, Necker–Cochin, Paris, Unité de Recherche Clinique, paris, France, ⁴Nephrology, HEGP, Paris, France, ⁵Internal medicine, Hôpital Bois Guillaume, ROUEN, France, ⁶Nephrology, Hôpital Rangueil, Toulouse, France, ⁷Nephrologie, Hôpital Clémenceau, CAEN, France, ⁸Internal medicine, Hôpital de l'Archet, NICE, France, ⁹Grenoble, Grenoble, France, ¹⁰Department of Internal Medicine, Edouard Herriot University Hospital, Hospices Civils de Lyon, Lyon cedex 03, France, ¹¹Internal Medicine, Hôpital de la côte de Nacre, Caen, France, ¹²Pôle médecine interne et gériatrique, pneumologie, Hôpital Bretonneau, Tours, France, ¹³Nephrology, Hôpital Civil, STRASBOURG, France, ¹⁴Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ¹⁵foch hospital, foch, France
Background/Purpose: Scleroderma renal crisis (SRC), a life-threatening complication of systemic sclerosis (SSc), arises despite therapy combining an angiotensin-converting–enzyme inhibitor (AECI) and/or dialysis. Endothelin-1 (ET-1), a…
Abstract Number: 2179 • 2013 ACR/ARHP Annual Meeting
Consensus: What Agent To Use When First-Line Vasodilatadors Fail In Raynaud´s Phenomenon Or Digital Ulcers Secondary To Juvenile Systemic Sclerosis?
Marìa M. Katsicas¹, Mariana Gonzalez² and Ricardo A. G. Russo³, ¹Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina, ²Immunology & Rheumatology, Hospital de Pediatría Garrahan, Buenos Aires, Argentina, ³Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina
Background/Purpose: Juvenile Systemic Sclerosis (JSS) is characterized by Raynaud`s phenomenon (RP) and digital ulcers (DU).Conventional therapy includes calcium channel blockers (CCB). A growing number of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].